| B35 | Bictegravir/emtricitabine/tenofovir alafenamide in patients with genotypic NRTI resistance | E-poster | Regimen simplification and switch studies |
| B35 | Switch to BIC/FTC/TAF in virally suppressed PLWH: efficacy and tolerability | E-poster | Regimen simplification and switch studies |
| B35 | Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide (BIC/F/TAF) for maintenance of viral suppression in adults with historical virological failure and K65N/R mutation | E-poster | Regimen simplification and switch studies |
| B35 | Switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in adults aged 65 years or older: week 96 results from an international, Phase 3b, open-label trial | E-poster | Regimen simplification and switch studies |
| B35 | Week 72 outcomes and COVID-19 impact from The BRAAVE 2020 study: a randomized switch to B/F/TAF in African American adults living with HIV | E-poster | Regimen simplification and switch studies |
| B35 | Successfully (and safely) enrolling a multi-center HIV antiretroviral clinical trial during the COVID-19 pandemic: lessons learned from Kenya | E-poster | Regimen simplification and switch studies |
| B35 | DTG+3TC in GEMINI-1&-2: HIV-1 replication at <50 c/mL and VL blips through 144 weeks | E-poster | Regimen simplification and switch studies |
| B35 | Metabolic health outcomes at week 96 in the TANGO Study, comparing a switch to DTG/3TC versus maintenance of TAF-based regimens | E-poster | Regimen simplification and switch studies |
| B35 | Low risk of losing the undetectable viral load status in people with HIV switching to dual therapy | E-poster | Regimen simplification and switch studies |
| B35 | Transition to DTG in Cote d'Ivoire: are women being left behind? | E-poster | Regimen simplification and switch studies |